Conjugated vaccines;Les vaccins conjugués

Therapie

Volumn 60, Issue 3, 2005, Pages 249-255

  Fritzell, Bernard ^a,b  

^a International Scientific and Clinical Affairs   (France)

^b International Scientific and Clinical Affairs   (France)

Author keywords

Conjugated polysaccharide vaccine; Effectiveness; Herd protection; Immune response; Immunisation programmes

Indexed keywords

BACTERIAL VACCINE; HAEMOPHILUS VACCINE; MENINGOCOCCUS VACCINE; STREPTOCOCCUS VACCINE; VACCINE;

BACTERIAL INFECTION; CONFERENCE PAPER; DRUG CONJUGATION; DRUG SURVEILLANCE PROGRAM; EPIDEMIC MENINGITIS; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNE SYSTEM; IMMUNITY; INCIDENCE; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION; IMMUNOLOGY; REVIEW;

HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; NEISSERIA MENINGITIDIS, SEROGROUP C; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 24944591311     PISSN: 00405957     EISSN: 00405957     Source Type: Journal    
DOI: 10.2515/therapie:2005032     Document Type: Conference Paper

References (30)

1. Georges S, Perrocheau A, Laurent E, et al. Infections invasives à H. influenzae, L. monocytogenes, N. meningitidis, S. pneumoniae, S. agalactiae et S. pyogenes en France en 2001-2002. Bulletin Epidémiologique Hebdomadaire 2004; 34: 164-8
2. Rijkers GT, Sanders EAM, Breukels MA, et al. Responsiveness of infants to capsular polysaccharides: impact on vaccine development. Rev Med Microbiol 1996; 7: 3-12
3. Peset Llopis MJ, Harms G, Hardonk MJ, et al. Human immune response to pneumococcal polysaccharides: complement-mediated localization preferentially on CD21-positive splenic marginal zone B cells and follicular dendritic cells. J Allergy Clin Immunol 1996; 97: 1015-24
4. Avery OT, Gorbel WF. Chemoimmunological studies on conjugated carbohydrate proteins. II. Immunological specificity of synthetic sugar-protein antigen. J Exp Med 1929; 50: 533-50
5. Schneerson R, Barrera O, Sutton A, et al. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide: protein conjugates. J Exp Med 1980; 152: 361-76
6. Black SB, Shinefield HR, Fireman B, et al. Efficacy in infancy of oligosaccharide conjugate H. influenzae type b (HbOC) vaccine in a United States population of 61,080 children: The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 1991; 10: 97-104
7. Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991; 324: 1767-72
8. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenzae type b tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997; 349: 1191-7
9. Vadheim CM, Greenberg DP, Eriksen E, et al. Eradication of H. influenzae type b disease in Southern California. Arch Pediatr Adolesc Med 1994; 148: 51-6
10. Scheifele DW. Recent trends in pediatric Haemophilus influenzae type b infections in Canada. Immunization Monitoring Program, Active (IMPACT) of the Canadian Paediatric Society and the Laboratory Centre for Disease Control. CMAJ 1996; 154: 1041-7
11. Teare EL, Fairley CK, White J, et al. Efficacy of Hib vaccine. Lancet 1994; 344: 828-9
12. Peltola H, Kilpi T, Anttila M. Rapid disappearance of H. influenzae type b meningitis after routine childhood immunization with conjugate vaccines. Lancet 1992; 340: 592-4
13. Infections invasives à H. influenzae, Listeria monocytogenes, méningocoque, pneumocoque, streptocoques groupe A et groupe B en France en 1996. Réseau EPIBAC. Epidémiologie des maladies infectieuses en France : maladies surveillées par le Réseau national de santé publique. Situation en 1996 et tendances évolutives récentes. Bull Epidemiol Hebd 1998; numéro spécial mars: 50
14. Takala AK, Eskola J, Leinonen M, et al. Reduction of oropharyngeal carriage of H. influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991; 164: 982-6
15. Murphy TV, Pastor P, Medley F, et al. Decreased Haemophilus colonization in children vaccinated with H. influenzae type b conjugate vaccine. J Pediatr 1993; 122: 517-23
16. Taunay A, Feldman RA, Bastos CO, et al. Avaliação do efeito protetor da vacina polissarídica antimeningocócica do grupo C, em crianças de 6 a 36 meses. Rev Inst Adolfo Lutz 1978; 38: 77-82
17. De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001; 285: 177-81
18. Richmond P, Borrow R, Miller E, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999; 179: 1569-72
19. English M, MacLennan JM, Bowen-Morris JM, et al. A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine 2000; 19: 1232-8
20. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364: 365-7
21. Ramsay ME, Andrews N, Kaczmarsksi EB, et al. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357: 195-6
22. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination: The UK Meningococcal Carriage Group. Lancet 2002; 359: 1829-31
23. Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326: 365-6
24. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children: Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19: 187-95
25. Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in northern California Kaiser Permanente. Pediatr Infect Dis J 2004; 23: 485-9
26. Mbelle N, Huebner RE, Wasas AD, et al. Immunogenicity and impact on nasopharyngeal carriage of nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999; 180: 1171-6
27. Dagan R, Givon-Lavi N, Zamir O, et al. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J 2003; 22: 532-9
28. Givon-Lavi N, Fraser D, Dagan R. Vaccination of day-care center attendees reduces carriage of Streptococcus pneumoniae among their younger siblings. Pediatr Infect Dis J 2003; 22: 524-31
29. Eskola J, Kilpi T, Palmu A, et al. Efficacy of pneumococcal conjugate vaccine against acute otitis medi. N Engl J Med 2001; 344: 403-9
30. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-46